Holen Sie sich die Stockscreener-App
12.45
4.89%
-0.64
Handel nachbörslich:
12.45
Schlusskurs vom Vortag:
$13.09
Offen:
$13.13
24-Stunden-Volumen:
1.14M
Relative Volume:
1.10
Marktkapitalisierung:
$858.15M
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-6.8407
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
+2.81%
1M Leistung:
-9.32%
6M Leistung:
+70.55%
1J Leistung:
+3.23%
1-Tages-Spanne:
$12.22
$13.34
1-Wochen-Bereich:
$11.55
$13.34
52-Wochen-Spanne:
$3.91
$14.91
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Pharmaceuticals Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
12.45 | 1.06B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
Is EyePoint Pharmaceuticals Inc. stock ready for breakoutJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - newser.com
EyePoint Pharmaceuticals Inc. stock outlook for YEARJuly 2025 PostEarnings & Short-Term Swing Trade Alerts - newser.com
The 8.1% Return This Week Takes EyePoint Pharmaceuticals' (NASDAQ:EYPT) Shareholders Five-year Gains to 211% - 富途牛牛
How EyePoint Pharmaceuticals Inc. stock performs in high volatility markets - newser.com
Has EyePoint Pharmaceuticals Inc. formed a bullish divergenceGold Moves & Free AI Powered Buy and Sell Recommendations - newser.com
EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals
EyePoint (NASDAQ: EYPT) to appear at Guggenheim, Stifel and Jefferies investor events - Stock Titan
What’s next for EyePoint Pharmaceuticals Inc. stock price2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Should you wait for a breakout in EyePoint Pharmaceuticals Inc.Market Sentiment Summary & Daily Profit Focused Screening - newser.com
Will EyePoint Pharmaceuticals Inc. stock split attract more investorsShort Setup & Weekly Chart Analysis and Guides - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock deliver compounding returnsPortfolio Performance Summary & Long-Term Capital Growth Ideas - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock a buy before new product rollout - newser.com
Combining price and volume data for EyePoint Pharmaceuticals Inc.July 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholder returns have been stellar, earning 212% in 5 years - simplywall.st
Eyepoint Pharmaceuticals (EYPT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
EyePoint Pharmaceuticals Inc Stock Analysis and ForecastCandlestick Pattern Analysis & Consistently Superior Profits - earlytimes.in
With 57% institutional ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a favorite amongst the big guns - Yahoo Finance
Will EyePoint Pharmaceuticals Inc. stock outperform growth indexesTrade Risk Report & Free High Return Stock Watch Alerts - newser.com
EyePoint Pharmaceuticals to Host Conference Call for Q3 2025 Financial Results on November 5, 2025 - Quiver Quantitative
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
EyePoint Pharmaceuticals (NASDAQ: EYPT) sets 8:30 a.m. ET call to discuss Q3 results - Stock Titan
Will EyePoint Pharmaceuticals Inc. stock see insider buyingJuly 2025 Momentum & Weekly High Momentum Picks - fcp.pa.gov.br
Is EyePoint Pharmaceuticals Inc. stock recession proof2025 Risk Factors & Verified Short-Term Trading Plans - fcp.pa.gov.br
Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):